SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?

Affiliations

¹ Division of Endocrinology, Diabetes, & Clinical Nutrition, Oregon Health & Science University, Portland, OR riddlem@ohsu.edu.
² American Diabetes Association, Arlington, VA.

Comment

Matthew C Riddle et al. Diabetes Care. 2018 Dec.

. 2018 Dec;41(12):2444-2447.

doi: 10.2337/dci18-0041.

¹ Division of Endocrinology, Diabetes, & Clinical Nutrition, Oregon Health & Science University, Portland, OR riddlem@ohsu.edu.
² American Diabetes Association, Arlington, VA.

No abstract available

Comment on

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Rosenstock J, et al. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30287422 Clinical Trial.
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators. Dandona P, et al. Diabetes Care. 2018 Dec;41(12):2552-2559. doi: 10.2337/dc18-1087. Epub 2018 Oct 23. Diabetes Care. 2018. PMID: 30352894 Clinical Trial.